Dramatic early improvement of psoriasis in an 11-year old boy after four doses of secukinumab following an alternative dosing scheme

J Eur Acad Dermatol Venereol. 2024 May;38(5):e399-e400. doi: 10.1111/jdv.19620. Epub 2023 Nov 21.

Authors

Julia Hoff¹, Leo Spora^{1

2}, Yongxing Fang^{2

3}, Marie-Charlotte Brüggen^{1

2

3}, Matthias Möhrenschlager¹

Affiliations

¹ Department of Dermatology, Hochgebirgsklinik, Davos, Switzerland.
² Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
³ Department of Dermatology, University of Zurich, Zurich, Switzerland.

PMID: 37909322
DOI: 10.1111/jdv.19620

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / therapeutic use
Child
Dermatologic Agents / administration & dosage
Dermatologic Agents / therapeutic use
Humans
Male
Psoriasis* / drug therapy

Substances

secukinumab
Antibodies, Monoclonal, Humanized
Dermatologic Agents